AQUEOUS PHARMA
HOME
FRESHKOTE
INNOVATIVE THERAPY FOR DRY EYE
   
UTILIZING DR. FRANK HOLLY'S UNPRECEDENTED KNOWLEDGE OF THE HUMAN TEAR FILM and OCULAR SURFACE
Aqueous Pharma was founded by Joe Echols, to focus on innovative therapy for dry eye syndrome on a global basis. To date, it owns the 3 patented artificial tear products & the patented ophthalmic solution preservative developed by Dr. Frank J. Holly, and has developed a new tear product, FRESHKOTE, reviewed on page 2 of this site.
  • Effective Artificial Tears Should Have:



  • Low Viscosity
  • Proper Oncotic Pressure depending on level of Dry Eye
  • Appropriate Synergistic Blending of Polymers
  • Added Nutrients or other components depending on etiology of Dry Eye type
  • Effective and Non-Irritating Preservative
  • Multi-dose packaging for convenience & cost efficiency
Dry eye is the most frequently diagnosed ocular disorder worldwide. Artificial tear products are front line therapy for this condition with this market showing growth of over 30% annually. Other tear products do not address healing of the ocular surface and only provide a temporary relief of symptoms; thereby providing the motivation for Dr. Holly to develop uniquely effective formulations. All 4 tear formulations are the first to enhance wettability of ocular surface cells. NUTRATEAR, containing Vitamin B12, is for mild dry eye & overuse of computers. DAKRINA, DWELLE & FRESHKOTE are the only products with high oncotic pressures (~65mm/Hg) and are for Moderate to Severe dry eye. DAKRINA has also been found effective in mucin-deficient dry eye due to its polymer-solubilized vitamin A; bio-available to the ocular surface and DAKRINA is the only tear clinically shown to increase goblet cell density in Sjogren's syndrome patients in a study at Duke University by Dr. Gary Foulks.  All 4 formulations are in compliance with the FDA Ophthalmic Monograph. FreshKote, Dakrina & Dwelle have been cleared for OTC Marketing in the UK by the MHRA (British Regulatory Authority) but are not yet on the market. FRESHKOTE (code: APL-105) was approved in all European Union Countries in November 2006. All 4 tears are preserved with the highly effective but yet totally non-irritating preservative, polyquaternium-42 (also known as polixetonium). For the USA, NutraTear, Dakrina & Dwelle are available from The Dry Eye Company - www.dryeyecompany.com . More information on FreshKote is on page 2 and at www.freshkote.com